The ISM2 antibody targets the Isthmin-2 (ISM2) protein, a secreted glycoprotein encoded by the ISM2 gene located on human chromosome 14. First identified in 2004. ISM2 belongs to the isthmin family, which includes ISM1 and ISM2. These proteins share a conserved domain structure, featuring a thrombospondin type-1 repeat (TSR) and an adhesion-associated domain. ISM2 is expressed in various tissues, including the brain, kidney, and reproductive organs, with roles in extracellular matrix interactions and cellular signaling. Research suggests ISM2 may influence angiogenesis, apoptosis, and tissue development, though its precise biological mechanisms remain under investigation. Antibodies against ISM2 are primarily used in research to study its localization, expression patterns, and functional pathways. Dysregulation of ISM2 has been implicated in cancers, such as glioblastoma and ovarian cancer, where altered expression correlates with tumor progression or metastasis. Additionally, ISM2 antibodies aid in exploring potential therapeutic applications, such as targeting tumor microenvironments. Despite progress, the full scope of ISM2’s physiological and pathological roles requires further elucidation, driving ongoing studies to map its interactions and validate its biomarker or therapeutic potential.